The earnings call reflects strong financial performance and strategic growth in key areas such as GLP-1 treatments and obesity care, supported by significant R&D achievements. However, challenges remain with increased carbon emissions, supply constraints, and issues in the rare diseases segment. Despite these challenges, the positive developments in sales, profit, and R&D outcomes suggest more highlights than lowlights.

Company Guidance

In the Novo Nordisk Q3 2024 earnings call, the company provided an optimistic outlook with a narrowed sales growth guidance, expecting a 23% to 27% increase at constant exchange rates. This growth is driven by a 24% sales increase in the first nine months of 2024, with North America Operations growing by 31% and International Operations by 15%. The operating profit is forecasted to grow between 21% and 27% at constant exchange rates. The company's strong performance is attributed to its GLP-1 treatments, with a notable 3x increase in patient reach over the last three years. Novo Nordisk is also focused on expanding its supply chain to meet the high demand, with capital expenditure expected to reach DKK 45 billion in 2024. Additionally, the free cash flow is projected to be between DKK 57 million and DKK 65 billion, reflecting the company's strategic investments and favorable U.S. rebate impacts.

Strong Sales and Profit Growth

Novo Nordisk reported a 24% sales growth and 22% operating profit growth in the first 9 months of 2024, driven by both North America Operations and International Operations.

Expansion of GLP-1 Treatments

The company has tripled its patient reach with GLP-1 treatments over the past three years, now serving around 11.5 million patients globally.

Significant R&D Achievements

Exciting readouts from Phase III trials, including SOUL, STRIDE, and ESSENCE, have shown substantial cardiovascular and kidney risk reductions with semaglutide.

Obesity Care Sales Surge

Obesity care sales increased by 44%, with International Operations showing a 95% increase, driven by the uptake of Wegovy.

Positive Regulatory Developments

Plans to file for regulatory approvals for oral semaglutide and semaglutide 2.4 mg based on successful trial outcomes.

---

Novo Nordisk (DE:NOVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:NOVA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 05, 2025	2024 (Q4)	0.84 / -	0.687	―	―	―
Nov 06, 2024	2024 (Q3)	0.84 / 0.85	0.682	23.91% (+0.16)
Aug 07, 2024	2024 (Q2)	0.68 / 0.63	0.612	3.13% (+0.02)	―
May 02, 2024	2024 (Q1)	0.72 / 0.78	0.622	25.62% (+0.16)
Jan 31, 2024	2023 (Q4)	0.64 / 0.69	0.414	65.74% (+0.27)
Nov 02, 2023	2023 (Q3)	0.65 / 0.68	0.403	69.29% (+0.28)
Aug 10, 2023	2023 (Q2)	0.65 / 0.61	0.383	59.90% (+0.23)
May 04, 2023	2023 (Q1)	0.60 / 0.62	0.423	46.94% (+0.20)
Feb 01, 2023	2022 (Q4)	0.40 / 0.41	0.346	19.67% (+0.07)
Nov 02, 2022	2022 (Q3)	0.39 / 0.40	0.393	2.44% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DE:NOVA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2024	€99.60	€97.60	-2.01%
Aug 07, 2024	€118.67	€109.20	-7.98%
May 02, 2024	€119.67	€118.17	-1.25%
Jan 31, 2024	€99.71	€105.17	+5.47%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---